본문 바로가기
KERD
논문KCI 등재

Cervical Cancer Screening after Perimenopause: How Is Human Papillomavirus Test Performed?

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

초록

Cervical cancer is the third most prevalent cancer in women around the world. Recently in Korea, the incidence of cervical cancer has decreased, but in all stages of cervical intraepithelial neoplasia (CIN), CIN has shown a 91% increase from 1999 to 2008. Persistent human papillomavirus (HPV) infection has been found to be the main cause of cervical cancer. HPV types 16 and 18 have been found in 70% of cervical cancer patients around the world. Cervical cancer screening such as cytology has limitations in terms of sensitivity and specificity. A discussion about the need for the HPV test is becoming active in order to compensate for the limitation of cytology. After the role of HPV in cervical cancer was identified, the importance of HPV detection test as a screening was emphasized. Several tests have been developed and each test has its own advantages and disadvantages, and new test method to overcome the disadvantages is still being developed. Today's guidelines and tests are those you would choose from among the large number of cervical cancer screening guidelines and tests, based on the consideration that the selected guidelines and the test are effective. (J Menopausal Med 2016;22:65-70)

Abstract

Cervical cancer is the third most prevalent cancer in women around the world. Recently in Korea, the incidence of cervical cancer has decreased, but in all stages of cervical intraepithelial neoplasia (CIN), CIN has shown a 91% increase from 1999 to 2008. Persistent human papillomavirus (HPV) infection has been found to be the main cause of cervical cancer. HPV types 16 and 18 have been found in 70% of cervical cancer patients around the world. Cervical cancer screening such as cytology has limitations in terms of sensitivity and specificity. A discussion about the need for the HPV test is becoming active in order to compensate for the limitation of cytology. After the role of HPV in cervical cancer was identified, the importance of HPV detection test as a screening was emphasized. Several tests have been developed and each test has its own advantages and disadvantages, and new test method to overcome the disadvantages is still being developed. Today's guidelines and tests are those you would choose from among the large number of cervical cancer screening guidelines and tests, based on the consideration that the selected guidelines and the test are effective. (J Menopausal Med 2016;22:65-70)

참고문헌 (26)

  1. Katki HA, "Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice", Lancet Oncol, 12, pp.663~672 (2011)
  2. Arbyn M, "Worldwide burden of cervical cancer in 2008", Ann Oncol, 22, pp.2675~2686 (2011)
  3. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2011", Cancer Research and Treatment, 46(2), pp.109~123 (2014), 대한암학회
  4. Smith JS, "Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update", Int J Cancer, 121, pp.621~632 (2007)
  5. 박준식, "부천 지역 폐경 전후 여성의 인유두종바이러스 감염 유병율", 대한폐경학회지, 17(3), pp.155~159 (2011), 대한폐경학회[DOI]
  6. Kim TH, "Media effect--Letter to the editor about the manuscript titled: increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine", Arch Gynecol Obstet, 289, pp.473~474 (2014)
  7. Smith RA, "Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening", CA Cancer J Clin, 65, pp.30~54 (2015)
  8. Satsuka A, "Life cycle of HPV governed by the differentiation program of epithelial cell", Uirusu, 58, pp.165~172 (2008)
  9. Burk RD, "Human papillomavirus genome variants", Virology, 445, pp.232~243 (2013)
  10. Guan P, "Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer", Int J Cancer, 131, pp.2349~2359 (2012)
  11. Carozzi F, "Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study", Eur J Cancer, 48, pp.1633~1637 (2012)
  12. Bodily J, "Persistence of human papillomavirus infection: keys to malignant progression", Trends Microbiol, 19, pp.33~39 (2011)
  13. Wright TC, Jr., "Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results", Am J Clin Pathol, 136, pp.578~586 (2011)
  14. Wright TC, "Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test", Gynecol Oncol, 136, pp.189~197 (2015)
  15. Moyer VA, "Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement", Ann Intern Med, 156, pp.880~891 (2012)
  16. Wright TC, Jr., "The ATHENA human papillomavirus study: design, methods, and baseline results", Am J Obstet Gynecol, 206, pp.46.e1~46.e11 (2012)
  17. Austin RM, "Increased cervical cancer risk associated with extended screening intervals after negative human papillomavirus test results: Bayesian risk estimates using the Pittsburgh cervical cancer screening model", J Am Soc Cytopathol, 5, pp.9~14 (2016)
  18. Baleriola C, "Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections", J Clin Virol, 42, pp.22~26 (2008)
  19. Davey DD, "Update on HPV test utilization", Am J Clin Pathol, 141, pp.759~ (2014)
  20. Davey DD, "2013 statement on human papillomavirus DNA test utilization", Am J Clin Pathol, 141, pp.459~461 (2014)
  21. Shepherd LJ, "Human papillomavirus--lessons from history and challenges for the future", J Obstet Gynaecol Can, 30, pp.1025~1033 (2008)
  22. Choi SD, "Cervical intraepithelial neoplasia based on array comparative genomic hybridization", Eur J Gynaecol Oncol, 35, pp.270~273 (2014)
  23. Gyllensten U, "Primary high-risk HPV screening for cervical cancer in post-menopausal women", Gynecol Oncol, 125, pp.343~345 (2012)
  24. Gyllensten U, "HPV test shows low sensitivity of Pap screen in older women", Lancet Oncol, 11, pp.509~510 (2010)
  25. Smith EM, "Persistent HPV infection in postmenopausal age women", Int J Gynaecol Obstet, 87, pp.131~137 (2004)
  26. 이재관, "Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition", Journal of Gynecologic Oncology, 24(2), pp.186~203 (2013), 대한부인종양학회

관련 논문AI추천

High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology공태욱, 김미선, 김영한, 김용범, 김자연, 김재원, 박미혜, 박주현, 이정호, 임명철, 홍준석대한산부인과학회 · Obstetrics & Gynecology Science2020 · 제63권 제2호부천 지역 폐경 전후 여성의 인유두종바이러스 감염 유병율김태희, 박준식, 이우석, 이해혁, 정수호대한폐경학회 · 대한폐경학회지2011 · 제17권 제3호Prevalence and Genotype Distribution of Cervical Human Papillomavirus DNA in Korean Women: A Multicenter Study최찬, 김동원, 김미진, 김애리, 김영옥, 김인선, 김혜선, 나서희, 박경신, 박용구, 박용욱, 박호성, 서광선, 손진희, 신미경, 오훈규, 윤기중, 윤혜경, 이시내, 이아원, 이효진, 정운원, 홍성란대한병리학회 · Journal of Pathology and Translational Medicine2009 · 제43권 제4호자궁경부암 진단에 HPV DNA검사의 역할이재관대한산부인과학회 · Obstetrics & Gynecology Science2006 · 제49권 제2호Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women김민정, 김선미, 김진주대한산부인과학회 · Obstetrics & Gynecology Science2013 · 제56권 제02호Proposal for cervical cancer screening in the era of HPV vaccination오영택, 이재관대한산부인과학회 · Obstetrics & Gynecology Science2018 · 제61권 제3호

이 간행물의 다른 논문 (12건)